BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid ...

CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce ...

BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release. The ...